DATA SHEET

Product Name:	BI-2536
Catalog #:	CV-1035
Alt:	CAS # 755038-02-9; 4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide
Molecular Mass:	521.7
Analysis:	>97% (HPLC); NMR (Conforms)
Supplied As:	Off-white powder
Resuspension:	May be dissolved in DMSO (20 mg/ml); or Ethanol (25 mg/ml)
Storage:	Store desiccated as supplied at -20°C for up to 2 years. Store solutions at -20°C for up to 3 months.
Description:	BI-2536 was originally reported as a potent (IC_{50}'s Plk1=0.83 nM, Plk2=3.5 nM and Plk3=9.0 nM)[1] and selective[2] Polo-like kinase inhibitor that caused mitotic arrest and apoptosis induction in various human cancer cell lines[1]. It was later found to be a potent inhibitor (IC_{50}=100 nM) of BET family member BRD4 and able to potently suppress c-Myc expression in MM.1S multiple myeloma cells[3]. BI-2536 destabilizes N-Myc by inhibiting the deactivation of the ubiquitin E3 ligase Fbw7 by Plk1[4].
References:	1. Steegmaier, M., et al., (2007) Curr. Biol., *17* : 316 2. Davis, M.I., et al., (2011) Nat. Biotechnol., *29* : 1046 3. Ciceri, P., et al., (2014) Nat. Chem. Biol., *10* : 305 4. Xiao, D., et al., (2016) Mol. Cell, *64* : 493

For research use only. Not for use in humans.

www.rpeptide.com
1050 Barber Creek • Bldg: 300 • Suite: 103 • Watkinsville • Georgia • 30677 • USA
Tel 678-753-0747 • Fax 678-753-0746 • E-mail sales@rpeptide.com